The future of breast cancer systemic therapy: the next 10&#160;years (Q38310565)

2 September 2017

1 reference

title

The future of breast cancer systemic therapy: the next 10 years (English)

1 reference

2 September 2017

1 reference

Melinda L Telli

1

1 reference

2 September 2017

George W Sledge

series ordinal

2

1 reference

2 September 2017

publication date

9 January 2015

1 reference

Journal of Molecular Medicine

2 September 2017

published in

1 reference

2 September 2017

volume

93

1 reference

2 September 2017

issue

2

1 reference

2 September 2017

page(s)

119-125

1 reference

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Adjuvant trastuzumab in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Activating HER2 mutations in HER2 gene amplification negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

HER2 discordance between primary and metastatic breast cancer: assessing the clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Estrogen receptor mutations and changes in downstream gene expression and signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Estrogen receptor (ER) α mutations in breast cancer: hidden in plain sight

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Angiogenesis sustains tumor dormancy in patients with breast cancer treated with adjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Controversies in clinical cancer dormancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Detection of cancer DNA in plasma of patients with early-stage breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Genomic analysis of circulating cell-free DNA infers breast cancer dormancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Molecular characterization of basal-like and non-basal-like triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Meta-analysis of BRCA1 and BRCA2 penetrance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Two decades after BRCA: setting paradigms in personalized cancer care and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1238-Y

Multigene assays for late recurrence of breast cancer

21 January 2018

1 reference

12 December 2020

Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression

1 reference

12 December 2020

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition

1 reference

12 December 2020

The concept of immunological surveillance

1 reference

12 December 2020

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

1 reference

12 December 2020

Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

1 reference

12 December 2020

The landscape of cancer genes and mutational processes in breast cancer

1 reference

12 December 2020

Circulating tumor cells in patients with breast cancer dormancy

1 reference

12 December 2020

10.1007/S00109-014-1238-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

2 September 2017

1041547467

0 references

1 reference